Media Press Pack

Open Orphan plc is the world leader in the testing of vaccines and antivirals using human challenge study clinical trials and is led by an experienced Leadership team

Please contact carol.dalton@cdzkteco.com if you require any further information or wish to schedule an interview. 

Please see below some useful resources such as the latest COVID Clear Test press release, approved company descriptions, the latest Open Orphan plc investor presentation, and images which can be used for editorial purposes as long as the connection to Quotient and/ or Open Orphan / hVIVO is clearly recognisable. Commercial use is prohibited.

Click here to see more recent Company Announcements.

COVID Clear Download

Latest Presentation Download

hVIVO Clear Logo Download

hVIVO Logo for Download

Open Orphan Logo for Download

Image: Quotient - instrument and lab technician

Image: Quotient Lab technicians blood sample, lab

Image: Quotient - close-up of microarray

Image: Quotient instrument and microarray cartridge loading dock

Image: hVIVO laboratory

Image: hVIVO – operation of MosaiQ instrument

Image: hVIVO – Adam French - Director Laboratory Operations

Image: hVIVO – Adam French - Director Laboratory Operations (2)

Image: hVIVO – Phlebotomy

Image: MosaiQ instrument at hVIVO

Image: hVIVO laboratory (2)

Image: Nurse with sample at hVIVO clinic

Image: FluCamp from hVIVO

Image: FluCamp from hVIVO (2)

Image: FluCamp from hVIVO (3)

Image: FluCamp from hVIVO (4)

Approved company descriptions

Open Orphan 75 words

Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Conducted from Europe's only 24-bedroom quarantine clinic with onsite virology providing individually isolated rooms and connected to our specialist laboratory facility. Which offers highly specialised virology and immunology laboratory services to support pre-clinical and clinical respiratory drug, antiviral, and vaccine discovery and development.

For more information please visit our Company Overview page

Quotient 75 words

Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced.  Quotient has two key product portfolios, ALBA by Quotient, quality blood bank reagents used in laboratories around the world, and MosaiQ™ by Quotient, the world’s first fully automated, consolidated testing platform. Building on from transfusion diagnostics experience, Quotient developed a serological antibody test in response to the global COVID-19 pandemic.
jurisdictions.

For More information please go to the Quotient website or see Quotient’s full Media Kit

Open Orphan 150 words

Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Conducted from Europe's only 24-bedroom quarantine clinic with onsite virology providing individually isolated rooms and connected to our specialist laboratory facility. Which offers highly specialised virology and immunology laboratory services to support pre-clinical and clinical respiratory drug, antiviral, and vaccine discovery and development. 

The Company has a leading portfolio of 8 viral challenge study models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD viral challenge models. As announced in early March, Open Orphan is rapidly advancing a number of Coronavirus challenge study models and expects to be helping many COVID-19 vaccine development companies to test their vaccines. 

Open Orphan comprises of two commercial specialist CRO services businesses (hVIVO and Venn) and is developing an early stage orphan drug genomics data platform business. 

For more information please visit our Company Overview page

Quotient 150 words

Building on 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and operational cost savings to laboratories around the world. Building on the experience from transfusion diagnostics, Quotient developed a serological test in response to the global COVID-19 pandemic. The MosaiQ COVID-19 Antibody Microarray is CE marked and available for distribution in Europe including Switzerland, and the UK. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania. The Quotient logo, Quotient MosaiQ and MosaiQ are trademarks or registered trademarks of Quotient Limited or its subsidiaries in various.

For More information please go to the Quotient website or see Quotient’s full Media Kit

Overview facts about hVIVO COVID Clear

  • The MosaiQ™ COVID-19 Antibody Microarray is a serological test for the detection of antibodies to SARS-COV-2
  • The assay is built to detect IgG & IgM directed at SARS-COV-2
  • The test is qualitative, giving positive or negative results
  • The microarray is run on the MosaiQ™ by Quotient instrument.
  • Up to 132 probes available per microarray
  • Up to 3,000 microarrays per instrument per day
  • First result delivered in <35 minutes, with subsequent results every 24 seconds
  • It offers continuous sample loading (120 samples)

Frequently Asked Questions

  • What type of test are being offered?
    • Blood draw-based testing as it is more sensitive and specific.
  • What platform does this test use?
    • Quotients MosaiQ™ 125 instrument, which uses a microarray technology that also has the capability as a multiplex system for use beyond COVID-19.
  • What evidence of validation exist for the assay?
    • The assay is completed using a CE IVD marked antibody detection microarray and has subsequently complete internal testing at hVIVO.
  • Is it CE marked?
    • Yes, it is the first CE IVD marked assay for COVID-19 Antibody testing. CE IVD mark achieved – 1st May 2020
  • What is the sensitivity and specificity of our test?
    • SARS-CoV-2 = 100% sensitivity, 99.8% specificity based on 161 samples tested, 30 of which were positive samples
  • How does it compare to the Roche test? What are the differences and advantages?
    • Roche is an Elecsys assay and Quotient MosaiQ™ 125 uses a microarray technology, also with capability as a multiplex system.
    • Roche Elecsys® Anti-SARS-CoV-2 is an immunoassay for the in-vitro qualitative detection of antibodies (including IgG) to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in human serum and plasma. Quotient MosaiQ detects IgG but also IgM for SARS-COV-2
    • Roche claim of 100% accuracy in PHE report was for samples over 42 days post symptoms / positive PCR test. The MosaiQ COVID-19 Microarrays have can detect antibodies from 9 days post symptoms / positive PCR test
  • What are the options for blood draw collection and shipping?
    • Through participants attending one of our partners/network of clinics
    • Direct clinical staff and shipping arranged by hVIVO at their place of business
    • Flexible option if business’s want to arrange their own clinical resource and arrange shipping themselves to save costs.
  • What are the sample handling, processing requirements around the samples taken?
    • Sample can be collected into serum separation tubs, maintained are +4 degrees centigrade and shipped at ambient temperature to hVIVO laboratory where they will be centrifuged and loaded onto the instrument.
  • What options are there for sample storage and shipment i.e. ambient, 2-4 degrees, frozen?
    • Sample can be shipped at ambient or +4 degrees C.
  • What considerations around timeframe from blood draw to hVIVO receipt are there for the options mentioned above?
    • The maximum stability for these types of samples is 9 days. Preference is for samples to be shipped same day of collection.
  • Are hVIVO using this test on their own staff?
    • Yes, the test has been offered to all hVIVO employees.
  • What is the turnaround time from hVIVO receipt of sample to result reported to client?
    • Results will be reported within 48 hours
  • How are the results managed and reported?
    • Results will be provided via one of our service partners and can either be as an individual result report or as a group of results for an employer.
  • What is the max capacity of quotient i.e. availability of kits etc should we need to run this at max output?
    • Supply of kits has been confirmed by Quotient and is part of our partnership agreement. We have capacity for up to 3000 samples tested per day.

Disclaimer

Offer ("Offer") for the entire issued and to be issued share capital of hVIVO plc ("Offeree") by Open Orphan plc ("Offeror")

ACCESS TO THIS AREA OF THE WEBSITE MAY BE RESTRICTED UNDER SECURITIES LAWS OR REGULATIONS IN CERTAIN JURISDICTIONS. THIS NOTICE REQUIRES YOU TO CONFIRM CERTAIN MATTERS (INCLUDING THAT YOU ARE NOT RESIDENT IN SUCH A JURISDICTION), BEFORE YOU MAY OBTAIN ACCESS TO THE INFORMATION ON THIS AREA OF THE WEBSITE. THESE MATERIALS ARE NOT DIRECTED AT OR TO BE ACCESSED BY PERSONS RESIDENT IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION OR WOULD RESULT IN A REQUIREMENT TO COMPLY WITH ANY CONSENT OR OTHER FORMALITY WHICH THE OFFEROR REGARDS AS UNDULY ONEROUS.

This website contains announcements, documents and other information (together the "Information") published by the Offeree and/or the Offeror in connection with the Offer. The Information is being made available in good faith and for information purposes only and is subject to the terms and conditions set out below.

The Information is not intended to, and does not, constitute or form any part of an offer to sell or otherwise dispose of or an invitation or the solicitation of an offer to purchase or otherwise acquire any securities, or the solicitation of a vote or approval pursuant to the Offer or otherwise in any jurisdiction in which such offer or solicitation is unlawful.

The Offer is expected to be made by means of an offer document (or potentially a scheme circular) which will contain the full terms and conditions of the Offer, including details on how it may be accepted. Any decision made in relation to the Offer should be made solely on the basis of the information provided in any such document.

Please read this notice carefully—it applies to all persons who view the website to access Information and, depending on who you are and where you live, it may affect your rights. This notice and the Information contained in this website may be altered or updated from time to time, and should be read carefully each time you visit this website. The Information speaks only at the date of the relevant information reproduced on this website. The Offeror does not have, and does not accept, any responsibility or duty to update any such Information and reserves the right to add to, remove or amend any Information reproduced on this website at any time and at its absolute discretion.

Access to the website

You are attempting to enter the part of this website that is designated for the publication of documents and information in connection with the Offer.

If you would like to view this part of the website, please read this notice carefully. This notice applies to all persons who view this part of the website and, depending on where you are located, may affect your rights or responsibilities. The Offeror reserves the right to amend or update this notice at any time and you should, therefore, read it in full each time you visit the site. In addition, the contents of this part of the website may be amended at any time, in whole or in part, at the sole discretion of the Offeror.

This part of the website contains electronic versions of materials relating to the Offer. The materials you are seeking to access are made available in good faith and for information purposes only and are subject to the terms and conditions set out below. The materials do not constitute an offer to sell or otherwise dispose of or an invitation or solicitation of any offer to purchase or subscribe for any securities pursuant to the Offer. Any person seeking to access this part of the website represents and warrants to the Offeror that they are doing so for information purposes only.

To allow you to view information about the Offer, you must read this notice and then click ‘I ACCEPT’. If you are unable to agree, you should click ‘I DECLINE’ and you will not be able to view information about the Offer.

Overseas jurisdictions

Viewing the materials you are seeking to access may be unlawful if you are resident or located in certain jurisdictions. In certain jurisdictions, only certain categories of persons may be allowed to view such materials. All persons resident or located outside of the UK who wish to view this part of the website must first satisfy themselves that they are not subject to any local requirements which prohibit or restrict them from doing so and should inform themselves about, and observe, any legal or regulatory requirements applicable in their jurisdiction.

These materials are not directed at or intended to be accessible by persons resident in any jurisdiction if to do so would constitute a violation of the relevant laws or regulations of that jurisdiction.

YOU SHOULD NOT DOWNLOAD, MAIL, FORWARD, DISTRIBUTE, SEND OR SHARE THE INFORMATION OR DOCUMENTS CONTAINED ON THIS PART OF THE WEBSITE TO ANY PERSON. IN PARTICULAR, YOU SHOULD NOT MAIL, FORWARD, DISTRIBUTE OR SEND THE INFORMATION OR DOCUMENTS CONTAINED THEREIN TO ANY JURISDICTION WHERE IT WOULD BE UNLAWFUL TO DO SO.

This part of the website contains information that has been prepared for the purposes of complying with English law and the City Code on Takeovers and Mergers ("Code") and the information disclosed may not be the same as that which would have been disclosed if this information had been prepared in accordance with the laws and regulations of any jurisdiction outside of England and Wales.

It is your responsibility to satisfy yourself as to the full observance of any relevant laws and regulatory requirements. If you are in any doubt, you should not continue to seek to access this part of the website.

Additional US information

The Offer relates to the securities of a company incorporated in England and Wales and is subject to UK procedural and disclosure requirements that are different from those of the United States ("US"). Any financial statements or other financial information included in this area of the website may have been prepared in accordance with non-US accounting standards that may not be comparable to the financial statements of US companies or companies whose financial statements are prepared in accordance with generally accepted accounting principles in the US. It may be difficult for US holders of shares to enforce their rights and any claims they may have arising under the US federal securities laws in connection with the Offer, since each of the Offeree and the Offeror are located in a country other than the US, and some or all of their officers and directors may be residents of countries other than the US. US holders of shares may not be able to sue Offeree and Offeror or their respective officers or directors in a non-US court for violations of the US securities laws. Further, it may be difficult to compel Offeree and Offeror and their respective affiliates to subject themselves to the jurisdiction or judgment of a US court.

Responsibility

In relation to any Offer-related materials accessible on this area of the website please note any statement of responsibility contained therein.

The documents included in this part of the website issued or published by the Offeror speak only at the specified date of the relevant document and the Offeror has, and accepts, no responsibility or duty to update or revise such documents (other than to the extent such duty arises as a matter of law or regulation).

In relation to any announcements or other Offer-related materials issued or published by the Offeror, or which relate to the Offeror or any of its subsidiaries, that are accessible on this area of the website, the only responsibility accepted by the Offeror and its directors is for the correctness and fairness of its reproduction.

Neither the directors of the Offeror, nor the Offeror, nor any affiliated companies of the Offeror, have reviewed, and no such person is or shall be responsible for or accepts any liability in respect of, any information contained on any other website which may be linked to or from this part of the website.

Forward-looking statements

The information included in this part of the website may contain statements about Offeree and Offeror that are or may be forward-looking statements. All statements other than statements of historical facts included in this document may be forward-looking statements. Without limitation, any statements preceded or followed by or that include the words ‘targets’, ‘plans’, ‘believes’, ‘expects’, ‘aims’, ‘intends’, ‘will’, ‘may’, ‘anticipates’, ‘estimates’, ‘projects’ or, words or terms of similar substance or the negative thereof, are forward-looking statements. Forward-looking statements include, but are not limited to, statements relating to the expected benefits of the acquisition to Offeree and Offeror, the expected timing and scope of the Offer and other statements other than historical facts. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations.

Such forward-looking statements are based on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. Many factors could cause actual results to differ materially from those projected or implied in any forward-looking statements. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Each of the Offeree, the Offeror and their respective members, directors, officers, employees, advisers and any person acting on behalf of one or more of them expressly disclaims any intention or obligation to update or revise any forward-looking or other statements contained herein, whether as a result of new information, future events or otherwise except as required by applicable law.

None of the Offeree, the Offeror and their respective members, directors, officers, employees, advisers and any person acting on their behalf provides any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this document will actually occur.

Other

If you are in any doubt about the contents of this part of the website or the action you should take, you should seek your own financial advice from an independent financial adviser ised under the Financial Services and Markets Act 2000 (as amended) or, if you are located outside the UK, from an appropriately ised independent financial adviser.

This notice shall be governed by and construed in accordance with English law.

Confirmation of understanding and acceptance

By clicking on I ACCEPT below, you:

  • confirm that you have read and understood the notice set out above and agree to be bound by its terms;
  • represent and warrant that you are not (nor do you act on behalf of someone who is) resident in any country that renders the accessing of the materials on this website or parts of it illegal;
  • agree that you will not print, download, or otherwise seek to copy, mail, forward, distribute or send any of the materials on this part of the website to any other person at any time; and
  • represent and warrant to the Offeror that you intend to access this part of the website for information purposes only.

If you are not able to give these confirmations, you should click on "I DECLINE" below.

Decline